Summary:
Hospital groups criticize proposed 340B changes, warning of increased burdens and uncertainty as program oversight may shift from HRSA to CMS.
Drug companies and hospitals are clashing over a new rebate model for discounted medications, which could change how hospitals pay for drugs and receive savings. A government pilot program is testing this approach with a small selection of drugs, sparking debate about costs, cash flow, and administrative hurdles. Curious about how this could impact hospitals and patients? Read on for the key details behind the controversy.
Source: 340B Rebate Models Arrive in the Form of a New Pilot Program, Nick Hut, HFMA, August 4, 2025; https://www.hfma.org/accounting-and-financial-reporting/340b-rebate-models-arrive-in-the-form-of-a-new-pilot-program/
Topics
Economics
Healthcare Process
Action Orientation
Related
The Collaboration Imperative: Why Healthcare Executives Must Unite Against an Existential ThreatWhat Every Company Can Learn from Private Equity‘Demon Copperhead’ Author Lays Foundation for Women in Appalachia To Beat AddictionRecommended Reading
Finance
The Collaboration Imperative: Why Healthcare Executives Must Unite Against an Existential Threat
Quality and Risk
Navigating the Physician Journey Across the Domains of Health Policy: Learning, Contributing, and Leading
Problem Solving
A Smarter Way to Disagree
Problem Solving
Coaching by Doctors for Doctors